title: Combination therapy for retinal vein occlusion.
authors.forename: Masahiko
authors.initials: M
authors.lastname: Shimura
authors.forename: Kanako
authors.initials: K
authors.lastname: Yasuda
authors.forename: Toru
authors.initials: T
authors.lastname: Nakazawa
authors.forename: Takayuki
authors.initials: T
authors.lastname: Takeshita
authors.forename: Takashi
authors.initials: T
authors.lastname: Shiono
authors.forename: Taijii
authors.initials: T
authors.lastname: Sakamoto
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016022:Case-Control Studies; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D017075:Laser Coagulation; D008269:Macular Edema / Q000188:drug therapy / Q000209:etiology / Q000601:surgery / Q000628:therapy*; D008297:Male; D011446:Prospective Studies; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab